SG11201805900YA - Inhibition of allergic reaction using an il-33 inhibitor - Google Patents

Inhibition of allergic reaction using an il-33 inhibitor

Info

Publication number
SG11201805900YA
SG11201805900YA SG11201805900YA SG11201805900YA SG11201805900YA SG 11201805900Y A SG11201805900Y A SG 11201805900YA SG 11201805900Y A SG11201805900Y A SG 11201805900YA SG 11201805900Y A SG11201805900Y A SG 11201805900YA SG 11201805900Y A SG11201805900Y A SG 11201805900YA
Authority
SG
Singapore
Prior art keywords
international
california
pct
inhibitor
allergic reaction
Prior art date
Application number
SG11201805900YA
Other languages
English (en)
Inventor
Marco Londei
Original Assignee
Anaptysbio Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Anaptysbio Inc filed Critical Anaptysbio Inc
Publication of SG11201805900YA publication Critical patent/SG11201805900YA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
SG11201805900YA 2016-01-14 2017-01-17 Inhibition of allergic reaction using an il-33 inhibitor SG11201805900YA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662278671P 2016-01-14 2016-01-14
PCT/US2017/013818 WO2017124110A1 (en) 2016-01-14 2017-01-17 Inhibition of allergic reaction using an il-33 inhibitor

Publications (1)

Publication Number Publication Date
SG11201805900YA true SG11201805900YA (en) 2018-08-30

Family

ID=59311527

Family Applications (2)

Application Number Title Priority Date Filing Date
SG11201805900YA SG11201805900YA (en) 2016-01-14 2017-01-17 Inhibition of allergic reaction using an il-33 inhibitor
SG10202006699XA SG10202006699XA (en) 2016-01-14 2017-01-17 Inhibition of allergic reaction using an il-33 inhibitor

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG10202006699XA SG10202006699XA (en) 2016-01-14 2017-01-17 Inhibition of allergic reaction using an il-33 inhibitor

Country Status (12)

Country Link
US (1) US20190016795A1 (https=)
EP (1) EP3402521A4 (https=)
JP (1) JP2019508382A (https=)
KR (1) KR20180101533A (https=)
CN (1) CN109475622A (https=)
AU (1) AU2017208099A1 (https=)
BR (1) BR112018014247A2 (https=)
CA (1) CA3011547A1 (https=)
EA (1) EA201891628A1 (https=)
MX (1) MX2018008732A (https=)
SG (2) SG11201805900YA (https=)
WO (1) WO2017124110A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201605580RA (en) 2014-01-10 2016-10-28 Anaptysbio Inc Antibodies directed against interleukin-33 (il-33)
JP2019516362A (ja) 2016-04-27 2019-06-20 ファイザー・インク 抗ｉｌ−３３抗体、その組成物、方法および使用
JOP20190093A1 (ar) 2016-10-28 2019-04-25 Lilly Co Eli أجسام مضادة لـ il-33 واستخداماتها
GB201712952D0 (en) * 2017-08-11 2017-09-27 Univ Edinburgh Immunomodulatory agent
EP3694877A1 (en) * 2017-10-09 2020-08-19 AnaptysBio, Inc. Anti-il-33 therapy for atopic dermatitis
WO2019183639A1 (en) * 2018-03-23 2019-09-26 Anaptysbio, Inc. Inhibition of allergic reaction to peanut allergen using an il-33 inhibitor
TW202021983A (zh) * 2018-09-21 2020-06-16 美商安納普提斯生物公司 用於嗜伊紅性氣喘之抗il-33療法
US20230099101A1 (en) * 2020-03-06 2023-03-30 The Regents Of The University Of Michigan Serine protease inhibitors for suppressing or preventing anaphylactic reaction

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7560530B1 (en) * 2006-07-20 2009-07-14 Schering Corporation IL-33 receptor
IE20080331A1 (en) * 2007-04-26 2009-07-08 Trinity College Dublin Products for altering cytokine activity and methods therefor
US9090694B2 (en) * 2012-04-30 2015-07-28 Janssen Biotech, Inc. ST2L antibody antagonists
AR091069A1 (es) * 2012-05-18 2014-12-30 Amgen Inc Proteinas de union a antigeno dirigidas contra el receptor st2
JO3532B1 (ar) * 2013-03-13 2020-07-05 Regeneron Pharma الأجسام المضادة لمضاد انترلوكين-33 واستعمالاتها
WO2014152195A1 (en) * 2013-03-15 2014-09-25 Regeneron Pharmaceuticals, Inc. Il-33 antagonists and uses thereof
KR101567758B1 (ko) * 2013-10-17 2015-11-11 인하대학교 산학협력단 항-Siglec-8 항체 또는 항-Siglec-F 항체, 및 항-IL-33 항체를 포함하는 알러지 질환의 예방 또는 치료용 조성물
BR112016013347B1 (pt) * 2013-12-26 2023-12-12 Mitsubishi Tanabe Pharma Corporation Anticorpo monoclonal humano neutralizante anti-il-33, composição farmacêutica, inibidor da expressão de citocinas, molécula de ácido nucleico, vetor, célula bacteriana transgênica, método de produção e uso dos mesmos
SG11201605580RA (en) * 2014-01-10 2016-10-28 Anaptysbio Inc Antibodies directed against interleukin-33 (il-33)

Also Published As

Publication number Publication date
AU2017208099A1 (en) 2018-08-09
CN109475622A (zh) 2019-03-15
EP3402521A4 (en) 2019-11-20
KR20180101533A (ko) 2018-09-12
JP2019508382A (ja) 2019-03-28
CA3011547A1 (en) 2017-07-20
WO2017124110A1 (en) 2017-07-20
US20190016795A1 (en) 2019-01-17
MX2018008732A (es) 2018-12-06
BR112018014247A2 (pt) 2018-12-18
EA201891628A1 (ru) 2018-12-28
SG10202006699XA (en) 2020-08-28
EP3402521A1 (en) 2018-11-21

Similar Documents

Publication Publication Date Title
SG11201805900YA (en) Inhibition of allergic reaction using an il-33 inhibitor
SG11201908391XA (en) Methods for modulating an immune response
SG11201811431VA (en) Multispecific antibodies against cd40 and cd137
SG11201901442RA (en) Heart valve docking coils and systems
SG11201909949XA (en) Targeted immunotolerance
SG11201908532UA (en) Macrocyclic compounds as ros1 kinase inhibitors
SG11201808222RA (en) Methods of treatment of cholestatic diseases
SG11201901494UA (en) Acid-alpha glucosidase variants and uses thereof
SG11201908846SA (en) Susceptor assembly for inductively heating an aerosol-forming substrate
SG11201809875VA (en) Compositions and methods for treating spinal muscular atrophy
SG11201811432WA (en) Rna for cancer therapy
SG11201804647TA (en) Dosing regimens for 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde
SG11201903012RA (en) Anti-c1s antibodies and methods of use thereof
SG11201807538PA (en) Crispr-cpf1-related methods, compositions and components for cancer immunotherapy
SG11201909495PA (en) Combination cancer immunotherapy with pentaaza macrocyclic ring complex
SG11201806342SA (en) Glucagon and glp-1 co-agonists for the treatment of obesity
SG11201909825VA (en) Hsp90 inhibitor oral formulations and related methods
SG11201407859YA (en) Methods of treating cancer using pd-l1 axis binding antagonists and vegf antagonists
SG11201407486PA (en) Compositions and methods for modulating utrn expression
SG11201808525UA (en) Anti-complement factor bb antibodies and uses thereof
SG11201805311XA (en) Method of treating a mammal, including human, against cancer using methionine and asparagine depletion
SG11201805001UA (en) Method of treating influenza a
SG11201808306PA (en) Treatment of cancer with tg02
SG11201808106YA (en) Use of masitinib for treatment of an amyotrophic lateral sclerosis patient subpopulation
SG11201907207UA (en) Pharmaceutical combinations comprising an anti-ly75 antibody